Evidence map›Paper›PMID 36849761›Full record

ArticleJournal of computer-aided molecular design2023

Inhibition mechanism of MRTX1133 on KRAS

Fanglin Liang, Zhengzhong Kang, Xianqiang Sun, Jiao Chen, Xuemin Duan, Hu He, Jianxin Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Targeted therapeutic strategies forTranslational lung cancer research · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fanglin LiangJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, China.
Zhengzhong KangAutoDrug Biotech Co. Ltd, Aly. 795 KangWei Rd., Pudong New Area, Shanghai, China.
Xianqiang SunAutoDrug Biotech Co. Ltd, Aly. 795 KangWei Rd., Pudong New Area, Shanghai, China. xianqiang.sun@autodrug.ai.
Jiao ChenAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu, China.
Xuemin DuanJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, China.
Hu HeSynrx Therapeutics (Hanghzou) CO. Ltd, ROOM 201, Building 4, Lane 1309, CangQian Rd., Yuhang Area, Hangzhou, China. hehu@synrx.cn.
Jianxin ChengJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, China. chengjx567@mail.ecust.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mutant KRAS was considered as an "undruggable" target for decades, especially KRAS

Indexed as

Molecular Dynamics SimulationProto-Oncogene Proteins p21(ras)Fungal ProteinsHeterocyclic Compounds, 2-RingNaphthalenesSulfhydryl CompoundsFungal ProteinsHeterocyclic Compounds, 2-RingKRASG12D inhibitor MRTX1133NaphthalenesProto-Oncogene Proteins p21(ras)Sulfhydryl CompoundsCluster analysisKRASG12DMarkov state modelMolecular dynamicsMRTX1133

Identifiers

PMID36849761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.